Lv5
896 积分 2024-05-08 加入
什么时候才能不上班
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
7天前
已完结
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non–Small-Cell Lung Cancer
7天前
已完结
Combination and Novel Pharmacologic Agents for OAB
7天前
已完结
Combination and Novel Pharmacologic Agents for OAB
11天前
已完结
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
12天前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
12天前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
12天前
已完结
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC
13天前
已完结
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
13天前
已完结
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non–Small-Cell Lung Cancer
13天前
已完结
皖公网安备34019202002308
